Charles Schwab Investment Management Inc. Has $2.77 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Charles Schwab Investment Management Inc. raised its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 0.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 293,936 shares of the biopharmaceutical company’s stock after buying an additional 2,060 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Theravance Biopharma were worth $2,766,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Algert Global LLC bought a new stake in shares of Theravance Biopharma during the third quarter worth about $851,000. Quantbot Technologies LP purchased a new stake in shares of Theravance Biopharma in the third quarter worth approximately $60,000. BNP Paribas Financial Markets lifted its holdings in shares of Theravance Biopharma by 88.9% in the third quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after purchasing an additional 143,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Theravance Biopharma by 29.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 3,827 shares during the last quarter. Finally, Martingale Asset Management L P boosted its position in shares of Theravance Biopharma by 14.4% during the third quarter. Martingale Asset Management L P now owns 54,450 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 6,870 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Stock Up 0.1 %

Shares of NASDAQ TBPH opened at $9.31 on Friday. The company has a market capitalization of $460.58 million, a PE ratio of -9.22 and a beta of 0.15. The stock’s 50 day moving average price is $9.39 and its 200-day moving average price is $9.08. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The business had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. As a group, research analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. The trade was a 1.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.